PROTONIX® Highlights

(pantoprazole sodium)

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use PROTONIX safely and effectively. See full prescribing information for PROTONIX.

PROTONIX (pantoprazole sodium) delayed-release tablets, for oral use
PROTONIX (pantoprazole sodium) for delayed-release oral suspension
Initial U.S. approval: 2000

INDICATIONS AND USAGE

PROTONIX is a proton pump inhibitor (PPI) indicated for the following:

•
Short-Term Treatment of Erosive Esophagitis Associated with Gastroesophageal Reflux Disease (GERD) (1.1)
•
Maintenance of Healing of Erosive Esophagitis (1.2)
•
Pathological Hypersecretory Conditions Including Zollinger-Ellison (ZE) Syndrome (1.3)

DOSAGE AND ADMINISTRATION

IndicationDoseFrequency
*
Controlled studies did not extend beyond 12 months

Short-Term Treatment of Erosive Esophagitis Associated With GERD (2.1)

  Adults

40 mg

Once Daily for up to 8 wks

  Children (5 years and older)

    ≥ 15 kg to < 40 kg

20 mg

Once Daily for up to 8 wks

    ≥ 40 kg

40 mg

Maintenance of Healing of Erosive Esophagitis (2.1)

  Adults

40 mg

Once Daily*

Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome (2.1)

  Adults

40 mg

Twice Daily

See full prescribing information for administration instructions

DOSAGE FORMS AND STRENGTHS

•
Delayed-Release Tablets: 20 mg and 40 mg pantoprazole (3)
•
For Delayed-Release Oral Suspension: 40 mg pantoprazole (3)

CONTRAINDICATIONS

•
Patients with known hypersensitivity to any component of the formulation or to substituted benzimidazoles (4)
•
Patients receiving rilpivirine-containing products (4,7)

WARNINGS AND PRECAUTIONS

•
Gastric Malignancy: In adults, symptomatic response does not preclude presence of gastric malignancy. Consider additional follow-up and diagnostic testing. (5.1)
•
Acute Tubulointerstitial Nephritis: Discontinue treatment and evaluate patients. (5.2)
•
Clostridium difficile-Associated Diarrhea: PPI therapy may be associated with increased risk of Clostridium difficile-associated diarrhea. (5.3)
•
Bone Fracture: Long-term and multiple daily dose PPI therapy may be associated with an increased risk for osteoporosis-related fractures of the hip, wrist or spine. (5.4)
•
Severe Cutaneous Adverse Reactions: Discontinue at the first signs or symptoms of severe cutaneous adverse reactions or other signs of hypersensitivity and consider further evaluation. (5.5)
•
Cutaneous and Systemic Lupus Erythematosus: Mostly cutaneous; new onset or exacerbation of existing disease; discontinue PROTONIX and refer to specialist for evaluation. (5.6)
•
Cyanocobalamin (Vitamin B-12) Deficiency: Daily long-term use (e.g., longer than 3 years) may lead to malabsorption or a deficiency of cyanocobalamin. (5.7)
•
Hypomagnesemia and Mineral Metabolism: Reported rarely with prolonged treatment with PPIs. (5.8)
•
Fundic Gland Polyps: Risk increases with long-term use, especially beyond one year. Use the shortest duration of therapy. (5.10)

ADVERSE REACTIONS

Most common adverse reactions are:

•
For adult use (>2%): headache, diarrhea, nausea, abdominal pain, vomiting, flatulence, dizziness, and arthralgia. (6.1)
•
For pediatric use (>4%): URI, headache, fever, diarrhea, vomiting, rash, and abdominal pain. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS

See full prescribing information for a list of clinically important drug interactions (7)

USE IN SPECIFIC POPULATIONS

Pregnancy: Based on animal data, may cause fetal harm. (8.1)

See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.

Revised: 6/2023

Find PROTONIX® medical information:

Find PROTONIX® medical information:

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

PROTONIX® Quick Finder

Prescribing Information
Download Prescribing Information

Health Professional Information

Highlights

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use PROTONIX safely and effectively. See full prescribing information for PROTONIX.

PROTONIX (pantoprazole sodium) delayed-release tablets, for oral use
PROTONIX (pantoprazole sodium) for delayed-release oral suspension
Initial U.S. approval: 2000

INDICATIONS AND USAGE

PROTONIX is a proton pump inhibitor (PPI) indicated for the following:

•
Short-Term Treatment of Erosive Esophagitis Associated with Gastroesophageal Reflux Disease (GERD) (1.1)
•
Maintenance of Healing of Erosive Esophagitis (1.2)
•
Pathological Hypersecretory Conditions Including Zollinger-Ellison (ZE) Syndrome (1.3)

DOSAGE AND ADMINISTRATION

IndicationDoseFrequency
*
Controlled studies did not extend beyond 12 months

Short-Term Treatment of Erosive Esophagitis Associated With GERD (2.1)

  Adults

40 mg

Once Daily for up to 8 wks

  Children (5 years and older)

    ≥ 15 kg to < 40 kg

20 mg

Once Daily for up to 8 wks

    ≥ 40 kg

40 mg

Maintenance of Healing of Erosive Esophagitis (2.1)

  Adults

40 mg

Once Daily*

Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome (2.1)

  Adults

40 mg

Twice Daily

See full prescribing information for administration instructions

DOSAGE FORMS AND STRENGTHS

•
Delayed-Release Tablets: 20 mg and 40 mg pantoprazole (3)
•
For Delayed-Release Oral Suspension: 40 mg pantoprazole (3)

CONTRAINDICATIONS

•
Patients with known hypersensitivity to any component of the formulation or to substituted benzimidazoles (4)
•
Patients receiving rilpivirine-containing products (4,7)

WARNINGS AND PRECAUTIONS

•
Gastric Malignancy: In adults, symptomatic response does not preclude presence of gastric malignancy. Consider additional follow-up and diagnostic testing. (5.1)
•
Acute Tubulointerstitial Nephritis: Discontinue treatment and evaluate patients. (5.2)
•
Clostridium difficile-Associated Diarrhea: PPI therapy may be associated with increased risk of Clostridium difficile-associated diarrhea. (5.3)
•
Bone Fracture: Long-term and multiple daily dose PPI therapy may be associated with an increased risk for osteoporosis-related fractures of the hip, wrist or spine. (5.4)
•
Severe Cutaneous Adverse Reactions: Discontinue at the first signs or symptoms of severe cutaneous adverse reactions or other signs of hypersensitivity and consider further evaluation. (5.5)
•
Cutaneous and Systemic Lupus Erythematosus: Mostly cutaneous; new onset or exacerbation of existing disease; discontinue PROTONIX and refer to specialist for evaluation. (5.6)
•
Cyanocobalamin (Vitamin B-12) Deficiency: Daily long-term use (e.g., longer than 3 years) may lead to malabsorption or a deficiency of cyanocobalamin. (5.7)
•
Hypomagnesemia and Mineral Metabolism: Reported rarely with prolonged treatment with PPIs. (5.8)
•
Fundic Gland Polyps: Risk increases with long-term use, especially beyond one year. Use the shortest duration of therapy. (5.10)

ADVERSE REACTIONS

Most common adverse reactions are:

•
For adult use (>2%): headache, diarrhea, nausea, abdominal pain, vomiting, flatulence, dizziness, and arthralgia. (6.1)
•
For pediatric use (>4%): URI, headache, fever, diarrhea, vomiting, rash, and abdominal pain. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS

See full prescribing information for a list of clinically important drug interactions (7)

USE IN SPECIFIC POPULATIONS

Pregnancy: Based on animal data, may cause fetal harm. (8.1)

See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.

Revised: 6/2023
Medication Guide

Health Professional Information

{{section_name_patient}}

{{section_body_html_patient}}

Resources

Didn’t find what you were looking for? Contact us.

MI Digital Assistant

Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine.

Call 800-438-1985*

*Speak with a Pfizer Medical Information Professional regarding your medical inquiry. Available 9AM-5Pm ET Monday to Friday; excluding holidays.

Medical Inquiry

Submit a medical question for Pfizer prescription products.

Report Adverse Event

Pfizer Safety

To report an adverse event related to the Pfizer-BioNTech COVID-19 Vaccine, and you are not part of a clinical trial* for this product, click the link below to submit your information:

Pfizer Safety Reporting Site

*If you are involved in a clinical trial for this product, adverse events should be reported to your coordinating study site.

If you cannot use the above website, or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at (800) 438-1985.

FDA Medwatch

You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatch or call (800) 822-7967.